Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0367 in pediatric Duchenne muscular dystrophy
NCT04184882Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing ASP0367 group with Placebo to ASP0367 group (2 arms). Primary endpoints: Treatment Emergent Adverse Events, Vital sign abnormalities and/or AEs and 6 more. Started Feb 2021; status: terminated.
02
Drugs
bocidelpar
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04184882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184882.